Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DWC202315
- Development stage
- Unknown
- Lead developer
- Daewoong Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DWC202315 is an investigational pharmaceutical agent undergoing bioequivalence and pharmacokinetics assessment in healthy adults. It was the subject of a randomized, open-label, oral, single-dose, crossover study to compare its safety and pharmacokinetic profile with another agent, DWJ1589. Detailed chemical properties, mechanism of action, and clinical indication remain unspecified as of the latest records; the agent appears to be developed by Daewoong Pharmaceutical, and its intended primary use is currently undefined but under evaluation in healthy volunteers for pharmacokinetic purposes[1][4].
- Brand names
- DWC202315DWC-202315DWC 202315
- Other names
- DWC202315DWC-202315DWC 202315
Beyond the preview
Go deeper on DWC202315.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DWC202315.